IPM Take
Cardiology may be approaching its Lp(a) moment. For years, elevated lipoprotein(a) has been recognised as a cardiovascular risk factor, but the practical question remained unclear: how high is high enough to meaningfully change clinical management? This new analysis suggests that 175 nmol/L may represent a threshold where cardiovascular risk rises substantially. That matters because a new generation of therapies specifically targeting Lp(a) is approaching the clinic. The challenge now shifts from proving Lp(a) matters to identifying which patients should be tested, monitored and eventually treated.
Executive Summary
Researchers presented new findings at SCAI 2026 showing that lipoprotein(a) levels of 175 nmol/L or higher were associated with a 31% increased risk of major adverse cardiovascular events. The analysis included more than 20,000 participants from the NIH-sponsored ACCORD, PEACE and SPRINT studies. Elevated risk was driven primarily by stroke and cardiovascular death and was most pronounced among patients with existing cardiovascular disease. The findings help define a clinically meaningful threshold for Lp(a)-associated risk and may support wider adoption of Lp(a) testing as emerging targeted therapies move through late-stage development.
Why it matters
- Clinicians: Provides a clearer threshold for identifying patients who may require intensified cardiovascular risk management.
- Policymakers: Strengthens arguments for broader implementation of once-in-a-lifetime Lp(a) screening programmes.
- Researchers: Supports ongoing development of precision medicine approaches targeting genetically determined cardiovascular risk.
- Patients: Highlights the importance of identifying inherited cardiovascular risk factors that may not be detected through traditional lipid testing.
Most cardiovascular prevention strategies focus on risk factors that can be modified.
Blood pressure can be lowered. LDL cholesterol can be reduced. Smoking can be stopped.
Lipoprotein(a), or Lp(a), is different.
Unlike most cardiovascular risk factors, Lp(a) levels are largely determined by genetics and remain relatively stable throughout life. For decades, researchers have known that elevated Lp(a) contributes to cardiovascular disease. The challenge has been determining exactly when elevated becomes dangerous enough to alter clinical decision-making.
New data presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2026 meeting may help answer that question.
Investigators analysed blood samples from more than 20,000 participants enrolled in the NIH-sponsored ACCORD, PEACE and SPRINT trials. After nearly four years of follow-up, individuals with Lp(a) levels of 175 nmol/L or higher experienced a 31% higher risk of major adverse cardiovascular events compared with those below the threshold.
Importantly, the increased risk was driven primarily by stroke and cardiovascular death rather than myocardial infarction. The association was also stronger among patients with established cardiovascular disease, suggesting that elevated Lp(a) may contribute significantly to residual risk even when conventional therapies are already in place.
The findings arrive at a critical moment for cardiovascular medicine.
Several novel therapies specifically targeting Lp(a), including pelacarsen, olpasiran, lepodisiran and zerlasiran, are progressing through advanced clinical development. Until recently, clinicians had few options beyond aggressive LDL lowering and management of traditional risk factors.
As targeted therapies move closer to regulatory review, identifying the patients most likely to benefit becomes increasingly important.
That creates a policy challenge.
Current European guidelines already recommend measuring Lp(a) at least once during adulthood, particularly in individuals with a family history of premature cardiovascular disease. Yet testing remains far from routine in many healthcare systems.
If emerging therapies demonstrate meaningful reductions in cardiovascular events, health systems may need to reconsider how inherited cardiovascular risk is detected and managed.
For IPM, this is another example of precision medicine moving beyond oncology.
The future of cardiovascular prevention may depend not only on lowering cholesterol broadly, but on identifying specific biological drivers of risk and matching patients to increasingly targeted interventions.
